secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0000950170-25-101618
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology confirms HNSCC enrollment guidance for Phase 1 MICVO trial after ClinicalTrials.gov revision
--------------------------------------------------------------------------------

- Revised ClinicalTrials.gov entry for MICVO (PYX-201) Phase 1 monotherapy trial reflects maximum patient enrollment per protocol.
- Company reaffirms prior HNSCC patient enrollment estimates for Part 2 dose expansion as disclosed in May 15, 2025 10-Q.
- No change to trial design or guidance; revision is administrative and consistent with industry practice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025101618/0000950170-25-101618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025101618/pyxs-20250804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-101618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer